| David Eugene Bacha, MD | |
|
471 N. Cleveland Massillon Rd., Akron, OH 44333 | |
| (330) 668-4045 | |
| (330) 668-2492 |
| Full Name | David Eugene Bacha |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 43 Years |
| Location | 471 N. Cleveland Massillon Rd., Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366448482 | NPI | - | NPPES |
| P00238133 | Other | OH | MEDICARE ID |
| 0639223 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 48308 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Summa Health System | Akron, OH | Hospital |
| Wooster Community Hospital | Wooster, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crystal Arthritis Center, Inc. | 4587609110 | 5 |
News Archive
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).
Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
Primary care physicians agree they have a role in addressing obesity, but say they do not have the right weight management resources. Obese or heavier adults take responsibility for weight loss, but adults who need to lose weight may lack information about effective weight loss methods and strategies. These findings and others come from new research commissioned and released today by the Strategies to Overcome and Prevent (STOP) Obesity Alliance, a project operating out of the Department of Health Policy at The George Washington University School of Public Health and Health Services.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Modified Release Compositions of Milnacipran", US Patent Application Number 12/211,780. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
› Verified 8 days ago
| Entity Name | Crystal Arthritis Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841247103 PECOS PAC ID: 4587609110 Enrollment ID: O20050624000042 |
News Archive
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).
Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
Primary care physicians agree they have a role in addressing obesity, but say they do not have the right weight management resources. Obese or heavier adults take responsibility for weight loss, but adults who need to lose weight may lack information about effective weight loss methods and strategies. These findings and others come from new research commissioned and released today by the Strategies to Overcome and Prevent (STOP) Obesity Alliance, a project operating out of the Department of Health Policy at The George Washington University School of Public Health and Health Services.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Modified Release Compositions of Milnacipran", US Patent Application Number 12/211,780. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Eugene Bacha, MD 471 N. Cleveland Massillon Rd, Akron, OH 44333 Ph: (330) 668-4045 | David Eugene Bacha, MD 471 N. Cleveland Massillon Rd., Akron, OH 44333 Ph: (330) 668-4045 |
News Archive
Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).
Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
Primary care physicians agree they have a role in addressing obesity, but say they do not have the right weight management resources. Obese or heavier adults take responsibility for weight loss, but adults who need to lose weight may lack information about effective weight loss methods and strategies. These findings and others come from new research commissioned and released today by the Strategies to Overcome and Prevent (STOP) Obesity Alliance, a project operating out of the Department of Health Policy at The George Washington University School of Public Health and Health Services.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Modified Release Compositions of Milnacipran", US Patent Application Number 12/211,780. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
› Verified 8 days ago
Dr. Michael A Pelini, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St, Ste 300, Akron, OH 44304 Phone: 330-376-7000 Fax: 330-376-1066 | |
David P. Lang, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 4125 Medina Rd, #200c, Akron, OH 44333 Phone: 330-665-8031 Fax: 330-665-8360 | |
Ms. Tiffany Mccann, D.O. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3561 | |
Jonathan Buggey, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St Ste 300, Akron, OH 44304 Phone: 724-422-6808 | |
Shamsa Baaj, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Mira Rohit Patel, DO Rheumatology Medicare: Medicare Enrolled Practice Location: 161 N Forge St Ste 198, Akron, OH 44304 Phone: 330-375-3039 | |
Richard J Streck, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, 5th Floor Ambulatory Care Center, Akron, OH 44307 Phone: 330-344-6015 Fax: 330-344-6820 |